Our Platform
Our approach
We provide access to centralised expertise and operational support to accelerate exceptional academic science into attractive biotech assets.
Our deep and broad expertise ensures that we can identify and develop promising therapeutic candidates efficiently, giving them the attention they deserve. For us, the right molecule, brought into Slingshot at the right time, means groundbreaking treatments, delivered earlier.
When looking for ideas; we seek:
-
World-leading scientists -
Targeted disease understanding -
Clear development pathways -
Significant unmet medical need
Test
Test
Test
Test
Our PROCESS
How we work to enable early science to thrive
Working with academics and pharma, we empower groundbreaking ideas, providing our programmes the required resources, the meaningful mentorship and the strategic support necessary to transform promising early-stage science into impactful biotech assets.
Early academic drug discovery projects
Programme entry
Securing groundbreaking early science discoveries from world-class scientists and key opinion leaders across the globe:
- Highest quality scientific hypotheses
- Innovative targets with strong linkage to mechanism of disease
- Novel therapeutic approaches
- Compelling areas of unmet need
Chemical matter
identified
Propulsion through the Slingshot platform
Programme acceleration
Moving at pace to accelerate initial ideas into robust candidate medicines:
- Proactive programme planning and risk management
- Multidisciplinary approach to programme progression; built around the founding science
- Structured milestones and programme governance
- A wealth of scientific and drug development advice, available from the outset
Development candidate identified
Individual programmes prepared for clinic
Programme development
High quality candidate medicines ready for clinical development:
- Robust target product profile
- Execution of clear, structured holistic drug development plan
- Delivery of compelling pre-clinical PoC data package
- Flexible models of partnership to progress through clinic and commercial launch
We are building a diverse pipeline of
high-potential programmes
A view from THE LAB
From science. To clinic.
Collaborating with the experienced drug development team at Slingshot allows our research team at the Crick to rapidly advance ALTx science and products towards the clinic.
Dr. Simon Boulton Founder of ALTx Therapeutics
